Psychometric validation of the French version of the side-effects and life satisfaction inventory (SEALS) in epileptic patients: Comparison with the QOLIE-31 inventory and a generic quality of life questionnaire

Epileptic Disorders

Volumn 7, Issue 2, 2005, Pages 103-113

  El Hasnaoui, Abdelkader ^a   Crespel, Arielle ^b   Daurès, Jean Pierre ^c   Baldy Moulinier, Michel ^b   Picot, Marie Christine ^b,d  

^a GLAXOSMITHKLINE   (France)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

^c UNIV MONTPELLIER   (France)

^d HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

Adverse drug effects; Epilepsy; French version; Psychometric validation; Quality of life

Indexed keywords

ANTICONVULSIVE AGENT;

ARTICLE; COGNITION; COMORBIDITY; COMPARATIVE STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DEPRESSION; DISEASE SEVERITY; DRUG TOLERABILITY; DYSPHORIA; EMOTION; EPILEPSY; FATIGUE; FRANCE; HEALTH STATUS; HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE; QUALITY OF LIFE IN EPILEPSY 31 QUESTIONNAIRE; QUESTIONNAIRE; RATING SCALE; RELIABILITY; REPRODUCIBILITY; SCORING SYSTEM; SIDE EFFECT; SIDE EFFECTS AND LIFE SATISFACTION INVENTORY; VALIDATION PROCESS;

ADOLESCENT; ADULT; CROSS-CULTURAL COMPARISON; EPILEPSY; FACTOR ANALYSIS, STATISTICAL; FEMALE; FRANCE; HUMANS; LANGUAGE; MALE; MIDDLE AGED; PERSONAL SATISFACTION; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS;

EID: 20444445148     PISSN: 12949361     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Baker G, Francis P, Middleton A, et al. Development of a patient-based symptom check list to quantify adverse effects in persons receiving antiepileptic drugs. Epilepsia 1993; 34: 18.
2. Baker GA, Smith DF, Dewey M, et al. The initial development of a health-related quality of life model as an outcome measure for epilepsy. Epilepsy Res 1993; 16: 65-81.
3. Baker GA, Jacoby A, Chadwick DW. The associations of psychopathology in epilepsy: a community study. Epilepsy Res 1996; 25: 29-39.
4. Baker GA, Jacoby A, Buck D, et al. Quality of life of people with epilepsy: a European study. Epilepsia 1997; 38: 353-62.
5. Brodie MJ, Richens A, Yuen AWC. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995; 345: 476-9.
6. Brown SW, Tomlinson LL. Anticonvulsant side effects: self-report questionnaire for use in community survey. Br J Clin Pract 1982; 18: 147-9.
7. Bryant-Comstock L, Kane K, Moorai A, et al. Improvement in quality of life with treatment resistant monotherapy patients on lamotrigine compared with valproate. Epilepsia 1999; 40(Suppl 2): 98.
8. Bucquet D, Condon S, Ritchie K. The French version of the Nottingham Health Profile. Soc Sci Med 1990; 30: 829-35.
9. Cramer JA, Perrine K, Devinsky O, et al. A brief questionnaire to screen for quality of life in epilepsy: the QOLIE-10. Epilepsia 1996; 37: 577-82.
10. Cramer JA, Perrine K, Devinsky O, et al. Development and cross-cultural translations of a 31-item quality of life in epilepsy inventory. Epilepsia 1998; 39: 81-8.
11. Devinski O, Vickrey BG, Cramer JA, et al. Development of the quality of life in epilepsy (QOLIE) inventory. Epilepsia 1995; 36: 1089-104.
12. Jackoby A, Baker JA, Smith DF, et al. Measuring the impact of epilepsy: the development of a new scale. Epilepsy Res 1994; 16: 83-8.
13. Gillham R, Baker C, Thompson P, et al. Standardisation of a self-report questionnaire for use in evaluating cognitive, affective and behavioral side-effects of anti-epileptic drug treatments. Epilepsy Res 1996; 24: 47-55.
14. Gillham R, Bryant-Comstock L, Kane K. Validation of the side effect and life satisfaction (SEALS) inventory. Seizure 2000; 9: 458-63.
15. Gillham R, Kane K, Bryant-Comstock L, et al. A double blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health-related quality of life as an outcome measure. Seizure 2000; 9: 375-9.
16. Gillian FG, Fessler AJ, Baker G, Vahle V, Carter J, Attarian H. Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial. Neurology 2004; 62: 23-7.
17. Hunt S, McEwen J, McKenna S. Measuring health status: a new tool for clinicians and epidemiologists. J R Coll Gen Pract 1985; 35: 185-8.
18. Jenkinson C, Wright L, Coulter A. The SF 36 health survey questionnaire....if used within its limits. BMJ 1993; 307: 449.
19. Kane K, Lee J, Bryant-Comstock L, et al. Assessing the psychometric characteristics of the Side Effect and Life Satisfaction Inventory (SEALS) in epilepsy: further validation from lamotrigine trials. Epilepsia 1996; 37(Suppl 5): 4.
20. Kugoh T. Quality of life in adult patients with epilepsy. Epilepsia 1996; 37(Suppl 3): 37-40.
21. Picot MC, Crespel A, Daurès JP, Baldy-Mouiinier M, El Hasnaoui A. Psychometric validation of the French version of the quality of life in epilepsy inventory (QOLIE-31): Comparison with a generic health related quality of life questionnaire. Epileptic Disord 2004; (in press).
22. Steiner TJ, Dellaportas CI, Findley LJ, et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double blind comparison with phenytoin. Epilepsia 1999; 40: 601-7.
23. Vickrey BG, Hays RD, Graber J, et al. A health-related quality of life instrument for patients evaluated for epilepsy surgery. Med Care 1992; 30: 299-319.
24. Vickrey BG, Perrine KR, Hays RD, et al. Quality of life in epilepsy (QOLIE-31) (version 1.0); scoring manual and patient inventory. Santa Monica, CA: RAND, 1993.